Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Mol Genet Metab Rep ; 6: 48-54, 2016 Mar.
Article in English | MEDLINE | ID: mdl-27014573

ABSTRACT

Sanfilippo syndrome type B (MPS IIIB) is a lysosomal storage disease caused by a deficiency of N-acetyl-glucosaminidase (NAGLU) activity. Since early therapeutic intervention is likely to yield the most efficacious results, we sought to determine the possible therapeutic utility of rAAV in early gene therapy based interventions. Currently, the application of recombinant adeno-associated virus (AAV) vectors is one of the most widely used gene transfer systems, and represents a promising approach in the treatment of MPS IIIB. From a translational standpoint, a minimally invasive, yet highly efficient method of vector administration is ideal. The thalamus is thought to be the switchboard for signal relay in the central nervous system (CNS) and therefore represents an attractive target. To identify an optimal AAV vector for early therapeutic intervention, and establish whether thalamic administration represents a feasible therapeutic approach, we performed a comprehensive assessment of transduction and biodistribution profiles of four green fluorescent protein (GFP) bearing rAAV serotypes, -5, -8, -9 and -rh10, administered bilaterally into the thalamus. Of the four serotypes compared, AAV8 and -9 proved superior to AAV5 and -rh10 both in biodistribution and transduction efficiency profiles. Genotype differences in transduction efficiency and biodistribution patterns were also observed. Importantly, we conclude that AAV8 and to a lesser extent, AAV9 represent preferable candidates for early gene therapy based intervention in the treatment of MPS IIIB. We also highlight the feasibility of thalamic rAAV administration, and conclude that this method results in moderate rAAV biodistribution with limited treatment capacity, thus suggesting a need for alternate methods of vector delivery.

2.
Gene Ther ; 23(3): 263-71, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26674264

ABSTRACT

Sanfilippo syndrome type B (mucopolysaccharidosis IIIB, MPS IIIB) is a lysosomal storage disease resulting from deficiency of N-acetyl-glucosaminidase (NAGLU) activity. To determine the possible therapeutic utility of recombinant adeno-associated virus (rAAV) in early gene therapy-based interventions, we performed a comprehensive assessment of transduction and biodistribution profiles of four central nervous system (CNS) administered rAAV serotypes, -5, -8, -9 and -rh10. To simulate optimal earliest treatment of the disease, each rAAV serotype was injected into the CNS of neonatal MPS IIIB and control animals. We observed marked differences in biodistribution and transduction profiles between the serotypes and this differed in MPS IIIB compared with healthy control mice. Overall, in control mice, all serotypes performed comparably, although some differences were observed in certain focal areas. In MPS IIIB mice, AAV8 was more efficient than AAV5, -9 and -rh10 for gene delivery to most structures analyzed, including the cerebral cortex, hippocampus and thalamus. Noteworthy, the pattern of biodistribution within the CNS varied by serotype and genotype. Interestingly, AAV8 also produced the highest green fluorescent protein intensity levels compared with any other serotype and demonstrated improved transduction in NAGLU compared with control brains. Importantly, we also show leakage of AAV8, -9 and -rh10, but not AAV5, from CNS parenchyma to systemic organs. Overall, our data suggest that AAV8 represents the best therapeutic gene transfer vector for early intervention in MPS IIIB.


Subject(s)
Dependovirus/genetics , Genetic Therapy , Mucopolysaccharidosis III/genetics , Mucopolysaccharidosis III/therapy , Skull/metabolism , Transduction, Genetic , Animals , Animals, Newborn , Mice , Mucopolysaccharidosis III/physiopathology
4.
Clin Pediatr (Phila) ; 34(9): 475-81, 1995 Sep.
Article in English | MEDLINE | ID: mdl-7586920

ABSTRACT

This study was conducted to determine whether intravenous theophylline, added to inhaled albuterol and intravenous methylprednisolone, provides a clinically significant benefit in the treatment of pediatric status asthmaticus. Patients aged 2 to 10 years were randomized to receive either intravenous theophylline or placebo. All patients received aerosolized albuterol and intravenous methylprednisolone. There was no difference between groups in the improvement of a clinical asthma score over time, in oxygen requirement, or in the number of albuterol treatments required. Theophylline group patients experienced more nausea, emesis, and insomnia. We conclude that there is no benefit in adding theophylline to treatment with methylprednisolone and albuterol for pediatric status asthmaticus. Furthermore, there are significantly more adverse effects associated with the use of theophylline.


Subject(s)
Bronchodilator Agents/administration & dosage , Status Asthmaticus/drug therapy , Theophylline/administration & dosage , Administration, Inhalation , Age Factors , Albuterol/administration & dosage , Child , Child, Preschool , Contraindications , Dose-Response Relationship, Drug , Double-Blind Method , Female , Glucocorticoids/administration & dosage , Humans , Injections, Intravenous , Male , Methylprednisolone/administration & dosage , Nausea/chemically induced , Placebos , Prospective Studies , Theophylline/adverse effects , Vomiting/chemically induced
5.
Curr Opin Pediatr ; 5(4): 503-17, 1993 Aug.
Article in English | MEDLINE | ID: mdl-8374681

ABSTRACT

This section features recent information in four areas of interest to the practicing pediatrician: animal-induced injuries and disease, neonatal jaundice, viral infections, and immunizations. The focus is on areas of major current discussion: the clinical spectrum and etiology of cat-scratch disease, the debate on new neonatal bilirubin recommendations, viral etiology of previously recognized clinical diagnoses, new immunization recommendations, and new vaccines. In addition, isolated but thought-provoking papers in the four areas over the past year are briefly discussed. By paying careful attention to highlighted articles, the busy practitioner should be able to keep abreast of rapid new developments.


Subject(s)
Gram-Negative Bacterial Infections , Immunization , Jaundice, Neonatal/therapy , Pediatrics/standards , Virus Diseases , Animals , Animals, Domestic , Child , Gram-Negative Bacterial Infections/diagnosis , Gram-Negative Bacterial Infections/etiology , Gram-Negative Bacterial Infections/therapy , Humans , Infant, Newborn , Virus Diseases/diagnosis , Virus Diseases/therapy
6.
Am J Sports Med ; 17(6): 770-2, 1989.
Article in English | MEDLINE | ID: mdl-2696376

ABSTRACT

Changes in blood, serum, and urine parameters that are usually associated with fluid and electrolyte balance were studied in 45 volunteers who ran the 1987 Pittsburgh Marathon. There were 39 males and 6 females. The mean age was 39.3 years. Their mean fluid intake was 1650 cc and the mean finishing time was 4 hours and 1 minute. The race was run in the rain with a temperature of 46 degrees F. When the prerace and postrace values of the runners were compared, significant increases were noted in the serum sodium, potassium, blood urea nitrogen (BUN), creatinine, uric acid, creatine phosphokinase (CPK), protein, plasma renin, vasopressin, and urinary potassium. Significant decreases were found in weight, blood pressure, and urinary sodium. No significant differences were noted in serum chloride, serum glucose, and hemoglobin/hematocrit. The mean weight loss of 1.9 kg was less than weight losses reported in marathons run under warmer conditions.


Subject(s)
Running , Water-Electrolyte Balance/physiology , Adult , Blood Pressure , Body Weight , Cold Temperature , Female , Hot Temperature , Humans , Male
SELECTION OF CITATIONS
SEARCH DETAIL
...